Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15 2024 - 8:30AM
Business Wire
- David Moatazedi, President and Chief Executive Officer of
Evolus, is first medical aesthetics leader to be a speaker at WWD
Beauty CEO Summit
- Evolus' flagship product, Jeuveau® is the fastest growing
aesthetic toxin in the U.S. for the last three years1
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
announced its participation in the Women’s Wear Daily (WWD) Beauty
CEO Summit. This summit brings together the leading retailers,
marketers, and creative minds across all categories to help prepare
for the next phase of global beauty while driving growth and
innovation today. At the global consumer beauty event, President
and Chief Executive Officer David Moatazedi is the first medical
aesthetics leader to be a speaker in a conversation with WWD
Editor-in-Chief Jenny Fine. Today also marks the fifth anniversary
since the launch of Evolus’ flagship neurotoxin, Jeuveau®, which is
the fastest growing toxin brand in the U.S. for the last three
years1.
"I am excited to lead a company in an industry that stands at
the intersection of beauty and medical aesthetics, that we define
as performance beauty,” said David Moatazedi, President and Chief
Executive Officer of Evolus. “Empowering individuals and redefining
beauty through our differentiated approach fuels our presence at
this global event, which is underscored by the strength of our
brand and our focus on the younger generation.”
“We are excited to have David Moatazedi on the mainstage at the
WWD Beauty CEO Summit,” said Amanda Smith, President, Fairchild
Media Group. “Evolus is becoming a real changemaker in the beauty
aesthetics space and we look forward to bringing this
science-driven innovation conversation to the WWD global thought
leader audience.”
Moatazedi continued, “Reflecting on five years of progress, I am
proud of what we have accomplished in such a short period of time
with our flagship product, Jeuveau®. As we celebrate this important
milestone, I am excited about the momentum we have built and our
evolution from a single-product aesthetics company to a
multi-product performance beauty innovator.”
The fireside chat can be accessed on the Investor Relations page
of the Evolus website here, which will be made available next week.
A replay of the webcast will be available for 90 days after the
date of the presentation.
1 Measured by comparing year-over-year revenue growth of each
aesthetic neurotoxin on the market for the entirety of each
comparable year.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company
evolving the aesthetic neurotoxin market for the next generation of
beauty consumers through its unique, customer-centric business
model and innovative digital platform. Our mission is to become a
global, multi-product aesthetics company based on our flagship
product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only
neurotoxin dedicated exclusively to aesthetics and manufactured in
a state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, and
the exclusive distributor in Europe of Estyme®, a line of unique
dermal fillers currently in late-stage development. Visit us at
www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or
Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™
is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong
Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese
Aesthetics S.A.S.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515169929/en/
Evolus Contacts:
Investors: Nareg Sagherian Vice
President, Head of Global Investor Relations and Corporate
Communications Tel: 248-202-9267 Email: ir@evolus.com
Media: Email: media@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Aug 2023 to Aug 2024